Studies immune cells in psoriasis skin during anti-IL-23 treatment
Examines skin biopsies from adults with psoriasis treated with an anti-IL-23 drug.
Plain-language title generated from the registry record
Registry title: Immune Infiltrate Analysis of Psoriasis Skin During Therapy With Anti-interleukin 23 (IL-23)
Key facts
- Where
- Rome, ItalySee the site
Where in Italy
- Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC DermatologiaRome, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Trial code
- NCT06792487
- Record updated
- 24 January 2025
- Original description
Psoriasis is an immune-mediated inflammatory skin disease characterized by the presence of erythematous and itchy plaques.Read full original descriptionShow less
Analysis of the Immune Infiltrate in Lesional Skin During Anti-interleukin 23 (IL-23) Therapy in Patients With Moderate-severe Plaque Psoriasis
Psoriasis is an immune-mediated inflammatory skin disease characterized by the presence of erythematous and itchy plaques.
Psoriasis has a multifactorial pathogenesis, environmental and genetic factors contribute to its development.
Although interleukin-23 blockade has been shown to be highly effective in the treatment of psoriasis, relapses have occurred during therapy.
Our study aims to identify the cellular source of key cytokines involved in disease recurrence or persistence of at least one psoriatic lesion in patients affected by moderate- severe psoriasis treated with an anti-IL-23 biologic drug. The immune infiltrate of resistant or relapsed plaques during anti-IL-23 therapy will be analysed from skin biopsies.
Inclusion: moderate-severe psoriasis PASI>10; anti IL 23 biologic therapy for at least 6 months (for the group under treatment); during therapy at least one area resistant to treatment or at least one flare of disease (for the group under treatment); patients able to express informed consent.
Exclusion: patients with complete response to anti IL23, without resistant plaques or disease flare-ups; patients unable to express informed consent.